261 related articles for article (PubMed ID: 21288628)
1. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis.
Koltun W; Maloney JM; Marr J; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2011 Apr; 155(2):171-5. PubMed ID: 21288628
[TBL] [Abstract][Full Text] [Related]
2. Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20 μg/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies.
Anttila L; Bachmann G; Hernádi L; Kunz M; Marr J; Klipping C
Eur J Obstet Gynecol Reprod Biol; 2011 Apr; 155(2):180-2. PubMed ID: 21277674
[TBL] [Abstract][Full Text] [Related]
3. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Gerlinger C; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
[TBL] [Abstract][Full Text] [Related]
5. A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.
Palli MB; Reyes-Habito CM; Lima XT; Kimball AB
J Drugs Dermatol; 2013 Jun; 12(6):633-7. PubMed ID: 23839178
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment.
Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
J Drugs Dermatol; 2009 Sep; 8(9):837-44. PubMed ID: 19746676
[TBL] [Abstract][Full Text] [Related]
7. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
Fenton C; Wellington K; Moen MD; Robinson DM
Drugs; 2007; 67(12):1749-65. PubMed ID: 17683173
[TBL] [Abstract][Full Text] [Related]
8. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
Thorneycroft lH; Gollnick H; Schellschmidt I
Cutis; 2004 Aug; 74(2):123-30. PubMed ID: 15379365
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
[TBL] [Abstract][Full Text] [Related]
10. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.
Lucky AW; Koltun W; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
Cutis; 2008 Aug; 82(2):143-50. PubMed ID: 18792547
[TBL] [Abstract][Full Text] [Related]
11. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R
Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
[TBL] [Abstract][Full Text] [Related]
12. YAZ and the novel progestin drospirenone.
Mishell DR
J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone.
Krunic A; Ciurea A; Scheman A
J Am Acad Dermatol; 2008 Jan; 58(1):60-2. PubMed ID: 17964689
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen.
Brucker C; Hedon B; The HS; Höschen K; Binder N; Christoph A
Contraception; 2010 Jun; 81(6):501-9. PubMed ID: 20472117
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate.
Vartiainen M; de Gezelle H; Broekmeulen CJ
Eur J Contracept Reprod Health Care; 2001 Mar; 6(1):46-53. PubMed ID: 11334476
[TBL] [Abstract][Full Text] [Related]
16. [Extracontraceptive benefits of EE/DRSP (Yaz) in 24+4 day regimen].
Bruni Bresciani V
Minerva Ginecol; 2010 Jun; 62(3):261-6. PubMed ID: 20595950
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
Coffee AL; Kuehl TJ; Willis S; Sulak PJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen.
Mansour D; Verhoeven C; Sommer W; Weisberg E; Taneepanichskul S; Melis GB; Sundström-Poromaa I; Korver T
Eur J Contracept Reprod Health Care; 2011 Dec; 16(6):430-43. PubMed ID: 21995590
[TBL] [Abstract][Full Text] [Related]
19. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
[TBL] [Abstract][Full Text] [Related]
20. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen).
Chaiyasit N; Taneepanichskul S
J Med Assoc Thai; 2010 May; 93(5):517-22. PubMed ID: 20524436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
